Clinical Trials at Duke University
As of August 2026, 163 paid clinical trials are recruiting at Duke University, located at 2301 ERWIN ROAD EMERGEENCY MEDICINE RESIDENCY, DURHAM, NC 27710-0001, phone (919) 681-2247 in Durham, North Carolina. Active studies at this site cover conditions such as Heart Failure, Breast Cancer and Prostate Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Durham
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
FlexED: Full Threshold ED Substudy
165 clinical trials at Duke University
·Clear filters·A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
GEMINI-NSCLC: NSCLC Biomarker Study
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
US National OCS Heart Perfusion (OHP) Registry
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
Diagnosing Epilepsy To EffeCT Change
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
QTX3034 in Patients With KRAS G12D Mutation
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)
Study of SGR-1505 in Mature B-Cell Neoplasms
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
Common conditions studied in Durham
- Heart Failure (20 active studies)
- Breast Cancer (19 active studies)
- Prostate Cancer (16 active studies)
- Cancer (12 active studies)
- Acute Myeloid Leukemia (11 active studies)
- Stroke (11 active studies)
Leading research sponsors in Durham
- Duke University
- VA Office of Research and Development
- National Cancer Institute (NCI)
- AstraZeneca
- Pfizer
Frequently asked questions
How many paid clinical trials are currently recruiting in Durham?
There are approximately 1,045 recruiting clinical trials in Durham, North Carolina listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Durham pay participants?
Most recruiting trials in Durham compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Durham?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Durham?
The most common conditions under active study in Durham include Heart Failure (20), Breast Cancer (19), Prostate Cancer (16), Cancer (12), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Durham?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Durham on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Durham?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Durham?
Recruiting research sites in Durham include Duke University Medical Center, Duke University, Duke University Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Durham right now?
The largest active categories in Durham are Cancer & tumors (286), Cardiovascular (95), Neurology & pain (67). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Duke University?
Duke University is located at 2301 ERWIN ROAD EMERGEENCY MEDICINE RESIDENCY, DURHAM, NC 27710-0001. Use the Google Maps link in the intro above to get directions.
How do I contact Duke University?
You can reach Duke University by phone at (919) 681-2247. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.